Latest Breaking News On - Post transplant lymphoproliferative disease - Page 1 : vimarsana.com

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress

Atara Biotherapeutics Announces First Quarter 2024 Financial Results and Operational Progress
eagletribune.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from eagletribune.com Daily Mail and Mail on Sunday newspapers.

United statesPascal touchonPierre fabreProgram in nonCorporate communications investor relationsInternational society for cell gene therapyAtara biotherapeutics incSecurities exchangeProgram in lupus nephritisProgram in severe systemic lupus erythematosusExchange commissionChief executive officerPost transplant lymphoproliferative diseaseBiologics license applicationObjective response rateLupus nephritis

IPE Health Sciences Research Symposium touts students, residents, faculty - News

IPE Health Sciences Research Symposium touts students, residents, faculty - News
campbell.edu - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from campbell.edu Daily Mail and Mail on Sunday newspapers.

David greenK paiged brownClaire oneillVictorm pulgarHayden tarpeySharon boydJamie chanHunnain siddiquiVanessa ayer millerChristian castilloTimothy mcmahan kingSophia millerShiela romanickPhilip longEdina djokicCarrie baker

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress

Atara Biotherapeutics Announces Fourth Quarter and Full Year 2023 Financial Results and Operational Progress
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United statesPierre fabrePascal touchonDrug administrationExchange commissionAtara biotherapeutics incInternational society for cell gene therapySecurities exchangeCorporate communications investor relationsProgram in lupus nephritisProgram in nonNephritis studyEnrolling with initial clinical data expectedRunway intoKey pipelineChief executive officer

Atara Biotherapeutics to Present Recent Progress and Key Upcoming Milestones at the 42nd Annual J P Morgan Healthcare Conference

Closing of Transaction with Pierre Fabre Laboratories to Expand Global Tab-cel® Partnership Tab-cel BLA on Track for Submission in Q2 2024 Following Positive New Data from Pivotal ALLELE.

United statesPierre fabrePascal touchonAtara biotherapeutics incSecurities exchangeExchange commissionOncology annual congressChief executive officerHealthcare conferenceLupus nephritisPost transplant lymphoproliferative diseaseBiologics license applicationObjective response ratePotential indicationHematological malignanciesAutoimmune conditions

Atara Biotherapeutics Announces Second Quarter 2023 Financial Results and Operational Progress

THOUSAND OAKS, Calif. (BUSINESS WIRE) Aug 8, 2023

United statesEric hyllengrenPascal touchonPierre fabreAlex chapmanInternational society of neuroimmunologyExchange commissionSecurities exchangeAtara biotherapeutics incChief executive officerPost transplant lymphoproliferative diseaseProgressive multiple sclerosisInternational societyGlial fibrillary acidic proteinInvestigational new drug applicationBayer collaboration agreements